IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11730708 B1

PDFFull Text
Date of Patent:
Aug. 22, 2023

Filed:

Sep. 17, 2020

Dosage form for use in treating or preventing of a disease

Applicant:

Evonik Operations Gmbh, Essen, DE;

Inventors:

Priyanka Haksar, Thane, IN;

Shraddha Joshi, Thane, IN;

Umesh Kapale, Solapur, IN;

Nilam Bharambe, Dombivali West, IN;

Ashish Guha, Mumbai, IN;

Vinay Jain, Mumbai, IN;

Assignee:

Evonik Operations GmbH, Essen, DE;

Attorney:

Grüneberg and Myers PLLC

Primary Examiner:

Susan T Tran

Int. Cl.
CPC ...
A61K 9/50 (2006.01); A61K 31/145 (2006.01); A61K 9/20 (2006.01); A61K 9/28 (2006.01); A61K 31/137 (2006.01); A61K 31/155 (2006.01); A61K 31/404 (2006.01); A61K 31/405 (2006.01); A61K 31/4402 (2006.01); A61K 31/4706 (2006.01); A61K 31/496 (2006.01); A61K 31/55 (2006.01); A61K 31/58 (2006.01); A61K 31/635 (2006.01); A61K 31/7048 (2006.01);
U.S. Cl.
CPC ...
A61K 31/145 (2013.01); A61K 9/2054 (2013.01); A61K 9/2813 (2013.01); A61K 9/2826 (2013.01); A61K 9/2846 (2013.01); A61K 9/2866 (2013.01); A61K 31/137 (2013.01); A61K 31/155 (2013.01); A61K 31/404 (2013.01); A61K 31/405 (2013.01); A61K 31/4402 (2013.01); A61K 31/4706 (2013.01); A61K 31/496 (2013.01); A61K 31/55 (2013.01); A61K 31/58 (2013.01); A61K 31/635 (2013.01); A61K 31/7048 (2013.01);
Abstract

A dosage form contains a biologically active ingredient for treating or preventing a disease in the animal or human body, where the treatment or prevention requires release of 50% or more of the biologically active ingredient in the small intestine within the pH range from 3 to 5.5. The dosage form contains: a) a core, containing the biologically active ingredient; b) an intermediate coating layer (ICL) onto or above the core, containing an alkaline agent; and c) an enteric coating layer (ECL) onto or above the intermediate coating layer, containing an enteric polymer. The relation of the alkaline agent to the enteric polymer is 5 to 95% when calculated by the formula:

Find Patent Forward Citations

Loading…